Clinical Network Services (CNS) Pty Ltd
14
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
14.3%
2 terminated/withdrawn out of 14 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
58%
7 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
Role: collaborator
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
Role: collaborator
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
Role: collaborator
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects
Role: collaborator
Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Role: collaborator
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Role: collaborator
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
Role: collaborator
Experimental Falciparum Transmission to Anopheles
Role: collaborator
SJ733 Induced Blood Stage Malaria Challenge Study
Role: collaborator
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers
Role: collaborator
Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety
Role: collaborator
MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Role: collaborator
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
Role: collaborator
A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265
Role: collaborator
All 14 trials loaded